Sibilia V, Pagani F, Lattuada N, Rapetti D, Guidobono F, Netti C
Department of Pharmacology, Chemotherapy and Medical Toxicology, University of Milano, Milan, Italy.
Brain Res. 2000 Jan 31;854(1-2):79-84. doi: 10.1016/s0006-8993(99)02286-6.
Binding studies for rat amylin (AMY) and salmon calcitonin (sCT) were performed on rat membranes prepared from pons and medulla oblongata of rats. The aim was to see whether specific binding sites for AMY and/or for sCT present in these areas could be relevant to some of the biological activities of the two peptides. Binding sites specific for [125I]AMY are present in the pons-medulla of rat brain as AMY, but not sCT, was able to displace radiolabeled AMY binding with an IC50 = 3.7+/-0.5x10(-10) M. In contrast, binding of [125I]sCT was displaced by both sCT and AMY, although with different potencies, the IC50 for sCT being 1+/-0.1x10(-11) M, and for AMY, 1.8+/-0.08x10(-7) M. The functional significance of the presence of these binding sites was evaluated in two different nociceptive tests, hot-plate and tail-flick. In the tail-flick test neither AMY (5-10 microg/rat, i.c.v.) nor sCT (10 microg/rat i.c.v.) showed antinociceptive activity, whereas in the hot-plate test AMY (10 microg/rat, i.c.v.) significantly increased the response latencies as did sCT (250 ng/rat, i.c.v.). These results demonstrated that a 40-fold greater dose of AMY is necessary to produce a comparable antinociceptive effect to that exerted by sCT. These findings are in accordance with the low affinity of AMY for sCT binding sites in rat pons-medulla. It is therefore suggested that the central inhibitory activity of AMY on pain perception involves interaction with sCT receptors whereas the selective AMY binding sites subserve other (as yet unknown) functions.
在从大鼠脑桥和延髓制备的大鼠膜上进行了大鼠胰淀素(AMY)和鲑鱼降钙素(sCT)的结合研究。目的是观察这些区域中存在的AMY和/或sCT的特异性结合位点是否与这两种肽的某些生物学活性相关。大鼠脑桥-延髓中存在对[125I]AMY特异的结合位点,因为AMY而非sCT能够以IC50 = 3.7±0.5×10(-10)M的浓度取代放射性标记的AMY结合。相反,[125I]sCT的结合被sCT和AMY两者取代,尽管效力不同,sCT的IC50为1±0.1×10(-11)M,AMY的IC50为1.8±0.08×10(-7)M。在两种不同的伤害感受测试(热板法和甩尾法)中评估了这些结合位点存在的功能意义。在甩尾测试中,AMY(5 - 10微克/大鼠,脑室内注射)和sCT(10微克/大鼠,脑室内注射)均未显示出抗伤害感受活性,而在热板测试中,AMY(10微克/大鼠,脑室内注射)和sCT(250纳克/大鼠,脑室内注射)一样显著增加了反应潜伏期。这些结果表明,产生与sCT相当的抗伤害感受作用需要AMY的剂量大40倍。这些发现与AMY对大鼠脑桥-延髓中sCT结合位点的低亲和力一致。因此,提示AMY对疼痛感知的中枢抑制活性涉及与sCT受体的相互作用,而选择性的AMY结合位点发挥其他(尚未知晓的)功能。